Nuvectis Pharma Inc (NVCT) — Cash Flow-to-Debt Ratio
Nuvectis Pharma Inc (NVCT) has a Cash Flow-to-Debt Ratio of -0.39x as of September 2025, meaning its operating cash flow of $-4.49 Million could theoretically repay 0% of its total liabilities ($11.58 Million) in one year. See Nuvectis Pharma Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Nuvectis Pharma Inc Cash Flow-to-Debt Ratio (2020–2024)
Historical debt coverage capacity for Nuvectis Pharma Inc across 5 annual periods. Also explore net asset momentum of Nuvectis Pharma Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Nuvectis Pharma Inc (2020–2024)
Year-by-year debt coverage analysis for Nuvectis Pharma Inc. For market capitalisation and broader financial context, see Nuvectis Pharma Inc (NVCT) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.38x | $-12.25 Million | $8.89 Million | ▲ +39.7% |
| 2023 | -2.28x | $-15.95 Million | $6.98 Million | ▼ -4.2% |
| 2022 | -2.19x | $-13.56 Million | $6.19 Million | ▼ -307.4% |
| 2021 | -0.54x | $-9.50 Million | $17.66 Million | ▼ -122.4% |
| 2020 | 2.40x | $24.00K | $10.00K | — |